Court Fight Over ‘Lowest Prices’ Claim

Pharmacist assists customer at pharmacy counter — Photo: Zamrznuti tonovi / Shutterstock

Washington just hardwired Medicare drug payments to foreign prices, but the claim that America now has the “lowest drug prices in the world” leaps far beyond what the rule can prove.

Story Snapshot

Medicare set a new model tying some Part B drug payments to foreign prices starting in 2027.
The policy targets high-spend, single-source drugs and only part of Medicare, not all drugs.
Drugmakers sued to block the model, creating legal risk and timing uncertainty.
Independent reviews say many listed prices are still higher than abroad for some drugs.

What The Government Actually Did

The Centers for Medicare and Medicaid Services finalized the Global Benchmark for Efficient Drug Pricing Model on September 30, 2026. The model links certain Medicare Part B drug rebate calculations to prices in nineteen peer countries. The Centers for Medicare and Medicaid Services scheduled the model to begin January 1, 2027, with the first performance year starting April 1, 2027. This is a defined path to test price effects inside Original Medicare, not a change to every drug price nationwide.

The Centers for Medicare and Medicaid Services said the model focuses on single-source drugs and sole-source biologic products with large Medicare spending. The framework narrows attention to seven therapeutic areas with products often exceeding one hundred million dollars in annual Part B spend. That focus aims at places where international gaps are big enough to matter for seniors and for taxpayers. But it does not convert every medicine or every market to foreign-linked rates.

How The Model Works And Where It Falls Short

The model replaces or modifies inflation-based rebates when a drug’s United States price runs above a benchmark built from foreign prices. The Centers for Medicare and Medicaid Services plans to use third-party data and, at first, voluntary manufacturer reports to set those comparisons. That data approach can limit completeness and slow verification. Early reporting also excludes many product types, such as some orphan-only drugs and plasma-derived products, which narrows impact.

The model applies only to selected geographic regions covering about one-quarter of Original Medicare Part B beneficiaries. It does not apply to Medicare Part D retail drugs, employer plans, or cash purchases. That means many patients will not see changes tied to this benchmark at the pharmacy. The rule is also a demonstration under the innovation center, so results will come in steps and may vary by area and product.

Legal Challenge And The Clock

The Pharmaceutical Research and Manufacturers of America sued the Department of Health and Human Services, the Centers for Medicare and Medicaid Services, and the innovation center in federal court. The case argues that the agency exceeded its authority with the foreign-benchmark design. That lawsuit, docketed as 1:26-cv-03498, could delay or reshape the model before results arrive. Policy risk like this often lands on patients and providers who need clear rules to plan care.

The U.S. drug reduction and pricing strategy centers on the Most-Favored-Nation (MFN) pricing initiative and ongoing federal negotiations, designed to align domestic prescription drug costs with the lowest prices paid among peer developed nations.

— ElizabethD (@ElizabethD57948) October 31, 2026

If courts pause the rule, rebates tied to foreign prices may not flow on time. If courts let it proceed, companies could adjust launch timing, discounts, or supply to protect revenue. Either path creates uncertainty. People across the political spectrum see a pattern here: sweeping promises at the podium, followed by narrow programs, carve-outs, and court fights that leave families asking when bills will actually fall.

Testing The “Lowest Prices” Claim

President Trump said Americans now have the world’s lowest drug prices. The Centers for Medicare and Medicaid Services materials do not report national price levels achieving that status. They describe a future model aimed at lowering some Part B drug payments starting in 2027. That gap between a broad claim and a targeted policy invites confusion and backlash if out-of-pocket costs do not drop fast or widely for most people.

Independent reviewers compared listed United States prices with foreign prices for selected drugs. The New York Times and German outlets reported that many prices shown to Americans still ran higher than in Germany for some medicines. A Kaiser Family Foundation comparison found the listed prices were the highest among peers for thirteen of thirty-two brand drugs, and above peer averages for fifteen, sometimes by large margins. Those findings challenge a blanket “lowest in the world” label today.

Why This Matters To Your Wallet

American brand-name drug prices have long been far above other wealthy countries, often two to three times higher. Families on both the right and the left see this as proof that the system serves insiders first. The new Medicare model could trim some bills for seniors who get Part B drugs in clinics. But the policy leaves many medicines, plans, and patients untouched. People paying at the counter may not feel relief soon, if at all.

Real accountability now depends on clear data. The Centers for Medicare and Medicaid Services should publish the covered-drug list, the foreign benchmarks, the rebates collected, and changes in patient cost sharing each quarter in 2027. Lawmakers should explain how they will extend savings beyond a pilot and protect access. Voters should watch the court case and the numbers, not the slogans. Promises are free. Lower bills are earned with proof.